- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04655261
Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia (FIRST)
Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Combination With Obinutuzumab in Population of Previously Untreated Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FIRST)
Chronic Lymphoid Leukemia (CLL) is the most common type of leukemia (cancer of blood cells) in adults affecting men more so than women. The main objective of this study is to assess the how effective venetoclax (Venclexta) in combination with Obinutuzumab is in treating Chronic Lymphocytic Leukemia (CLL). Effectiveness is assessed by achievement of best response.
Venetoclax is an approved drug developed for the treatment of CLL. Approximately 50 adult participants with previously untreated CLL will be enrolled in approximately 10 to 15 sites in Russian Federation.
Participants will receive oral venetoclax tablets in combination with intravenous (IV) Obinutuzumab as prescribed by the physician prior to enrolling in this study in accordance to the local practice and label.
There may be a higher burden for participants in this study compared to standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Sankt-Peterburg, Ryska Federationen, 191024
- Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 231127
-
Tula, Ryska Federationen, 300053
- Tula Regional Clinical Hospital /ID# 231128
-
-
Moskva
-
Moscow, Moskva, Ryska Federationen, 125284
- Moscow State budget healthcare /ID# 226058
-
-
Volgogradskaya Oblast
-
Volgograd, Volgogradskaya Oblast, Ryska Federationen, 400138
- Regional Children's Clinical Hospital of Volgograd /ID# 238328
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Confirmed diagnosis of previously untreated Chronic Lymphocytic Leukemia (CLL).
- Participant for whom the physician has decided to initiate CLL treatment with Venetoclax combo therapy with Obinutuzumab, according to approved local label up to 4 weeks (28 days) after Obinutuzumab treatment initiation.
Exclusion Criteria:
- Contraindications to Venclexta (Venetoclax) as listed on the approved local label in Russian Federation.
- Creatinine Clearance < 30 milliLitres/minute.
- Richter syndrome or Transformation of CLL to aggressive non-Hodgkin lymphoma.
- Participating in a clinical trial with an investigative drug for CLL.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
---|
Participants Treated With Venetoclax + Obinutuzumab
Participants will receive venetoclax (Venclexta) in combination with Obinutuzumab according to local label.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants Achieving Overall Response Rate (ORR) Best Response
Tidsram: Up to approximately 36 Months
|
ORR is defined as complete remission (CR) + complete remission with incomplete bone marrow recovery (CRi) + partial remission (PR) + nodular partial remission (nPR).
|
Up to approximately 36 Months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants Achieving Objective Response Rate (ORR)
Tidsram: Up to 12 Months
|
ORR is defined as CR + CRi + PR + nPR.
|
Up to 12 Months
|
Time to First Response
Tidsram: Up to approximately 36 Months
|
Time to first response is defined as number of days from first venetoclax intake to first response.
|
Up to approximately 36 Months
|
Time to Best Response
Tidsram: Up to approximately 36 Months
|
Time to best response is defined as number of days from first venetoclax intake to best response (CR, CRi, PR, nPR).
|
Up to approximately 36 Months
|
Duration of Response (DoR)
Tidsram: Up to approximately 36 Months
|
Duration of Response (DoR) is defined as number of days from first response to disease progression or death from any cause, whichever comes first.
|
Up to approximately 36 Months
|
Time to Next Treatment
Tidsram: Up to approximately 36 Months
|
Time to next treatment is defined as number of days from first venetoclax intake to first intake of next treatment including death from any cause.
|
Up to approximately 36 Months
|
Minimal Residual Disease (MRD)
Tidsram: Up to 36 Months
|
Percentage of participants achieving MRD (CLL < 10000 leucocytes) in the bone marrow, peripheral blood, either and both will be assessed.
|
Up to 36 Months
|
Overall Survival (OS)
Tidsram: Up to 36 Months
|
OS is defined as the number of days from the date of first dose to the date of the observational period end or death for all dosed participants.
|
Up to 36 Months
|
Progression-Free Survival (PFS)
Tidsram: Up to 36 Months
|
PFS is defined as the interval (in days) between the first treatment day to the first sign of disease progression or death from any cause.
|
Up to 36 Months
|
Number of Participants With Adverse Events (AEs)
Tidsram: Up to approximately 36 Months
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
The investigator assesses the relationship of each event to the use of study.
A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.
|
Up to approximately 36 Months
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P20-486
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kronisk lymfatisk leukemi (KLL)
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.IndragenKronisk lymfatisk leukemi | Litet lymfocytiskt lymfom | CLL | CLL/SLL | SLLFörenta staterna
-
University of California, IrvineUnited States Department of DefenseAktiv, inte rekryterandeAkut myeloid leukemi | Kronisk lymfatisk leukemi | AML, vuxen | CLL | KLL, återfall | CLL, eldfastFörenta staterna
-
Weill Medical College of Cornell UniversityTG Therapeutics, Inc.AvslutadKronisk lymfatisk leukemi | CLL/SLL | CLL-progressionFörenta staterna
-
European Society for Blood and Marrow TransplantationEuropean Research Initiative on CLLAvslutadCLLTyskland, Storbritannien, Nederländerna, Finland, Sverige, Danmark, Israel
-
Virginia Commonwealth UniversityGilead SciencesIndragenKronisk lymfatisk leukemi | Refraktär kronisk lymfatisk leukemi | Litet lymfocytiskt lymfom | CLL | Refraktärt litet lymfocytiskt lymfom | SLL | Återfall av CLL | Återfallande kronisk lymfatisk leukemi | Återfall av litet lymfocytiskt lymfom
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRekryteringKronisk lymfatisk leukemi | CLLItalien
-
Arbeitsgemeinschaft medikamentoese TumortherapieCelgeneAvslutadKronisk lymfatisk leukemi | CLLÖsterrike
-
Bnai Zion Medical CenterRambam Health Care Campus; Hadassah Medical Organization; Rabin Medical Center och andra samarbetspartnersOkänd
-
Genta IncorporatedAvslutadKronisk lymfatisk leukemi | CLLFörenta staterna
-
M.D. Anderson Cancer CenterGlaxoSmithKlineAvslutad